Filing Flows › TG Therapeutics (TGTX) › Q1 2026 › vs Q4 2025
TG Therapeutics (TGTX) Q1 2026 vs Q4 2025 (quarter over quarter)
TG Therapeutics's revenue rose $12.3M (+6%) from $193M in Q4 2025 to $205M in Q1 2026. The biggest changes: Product +$12.2M (+6%); License +$149K (+4%). Operating margin 17.0% against 26.2% (-9.2 pts).
TG Therapeutics, Q1 2026: revenue $205M (+70% year over year), operating margin 17.0%, net earnings $19.8M, operating cash flow −$17.9M. The chart draws each line against Q4 2025, the increases inside each band.
Margins
| Q1 2026 | Q4 2025 | Change | |
|---|---|---|---|
| Operating margin | 17.0% | 26.2% | -9.2 pts |
| Net margin | 9.7% | 12.0% | -2.3 pts |
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Product | $201M | $189M | $12.2M | +6% |
| License | $3.6M | $3.5M | $149K | +4% |
| Revenue | $205M | $193M | $12.3M | +6% |
| Operating profit | $34.8M | $50.5M | −$15.7M | -31% |
| Costs & expenses | $170M | $142M | $28.0M | +20% |
| Pre-tax earnings | $20.4M | $45.1M | −$24.7M | -55% |
| Other expense, net | $14.4M | $5.4M | $9.0M | +167% |
| Cost of revenue | $33.5M | $38.1M | −$4.6M | -12% |
| Research & development | $48.4M | $41.2M | $7.2M | +17% |
| SG&A | $88.2M | $62.7M | $25.5M | +41% |
| Net earnings | $19.8M | $23.0M | −$3.3M | -14% |
| Income tax | $586K | $22.1M | −$21.5M | -97% |
| Operating cash sources | $57.7M | $19.0M | $38.6M | +203% |
| Depreciation & amortization | $32K | $21K | $11K | +52% |
| Share-based compensation | $19.9M | $15.7M | $4.3M | +27% |
| Cash used in operations | $17.9M | −$19.7M | $37.6M | — |
| Working capital & other | $57.7M | $19.0M | $38.6M | +203% |
Questions
How much did TG Therapeutics's revenue grow quarter over quarter in Q1 2026?
TG Therapeutics's revenue rose $12.3M (+6%) from $193M in Q4 2025 to $205M in Q1 2026.
What drove TG Therapeutics's revenue change in Q1 2026?
Product +$12.2M (+6%); License +$149K (+4%).